Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 4, Pages 469-476
Publisher
Informa UK Limited
Online
2018-03-15
DOI
10.1080/14712598.2018.1452908
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
- (2018) L Clifford McDonald et al. CLINICAL INFECTIOUS DISEASES
- Emerging monoclonal antibodies against Clostridium difficile infection
- (2017) Séverine Péchiné et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab
- (2017) Lorraine D. Hernandez et al. JOURNAL OF MOLECULAR BIOLOGY
- Effects of control interventions on Clostridium difficile infection in England: an observational study
- (2017) Kate E Dingle et al. LANCET INFECTIOUS DISEASES
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
- (2017) Mark H. Wilcox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection
- (2017) Wesley D. Kufel et al. PHARMACOTHERAPY
- Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection
- (2017) Raseen Tariq et al. JAMA Internal Medicine
- Virulence factors of Clostridium difficile and their role during infection
- (2016) Claire Janoir ANAEROBE
- Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection
- (2016) Colleen R. Kelly et al. ANNALS OF INTERNAL MEDICINE
- Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin
- (2016) Peter Warn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibodies to Toxin B Are Protective AgainstClostridium difficileInfection Recurrence
- (2016) Swati B. Gupta et al. CLINICAL INFECTIOUS DISEASES
- Editorial Commentary: Where to Place the New Treatments forClostridium difficileInfection?
- (2016) Oliver A. Cornely et al. CLINICAL INFECTIOUS DISEASES
- Bezlotoxumab: First Global Approval
- (2016) Anthony Markham DRUGS
- A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection
- (2016) Sahil Khanna et al. JOURNAL OF INFECTIOUS DISEASES
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Breakthroughs in the treatment and prevention of Clostridium difficile infection
- (2016) Larry K. Kociolek et al. Nature Reviews Gastroenterology & Hepatology
- CdtR Regulates TcdA and TcdB Production in Clostridium difficile
- (2016) Shelley A. Lyon et al. PLoS Pathogens
- The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection
- (2016) Mária Džunková et al. Frontiers in Cellular and Infection Microbiology
- Receipt of Antibiotics in Hospitalized Patients and Risk for Clostridium difficile Infection in Subsequent Patients Who Occupy the Same Bed
- (2016) Daniel E. Freedberg et al. JAMA Internal Medicine
- Clostridium difficile infection
- (2016) Wiep Klaas Smits et al. Nature Reviews Disease Primers
- The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia
- (2016) Carrie A. Cowardin et al. Nature Microbiology
- Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection
- (2016) Lauren Lapointe-Shaw et al. PLoS One
- Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrentClostridium difficileinfection
- (2015) G. Cammarota et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Recurrent Clostridium difficile infection: From colonization to cure
- (2015) Kelsey Shields et al. ANAEROBE
- Interactions Between the Gastrointestinal Microbiome and Clostridium difficile
- (2015) Casey M. Theriot et al. Annual Review of Microbiology
- Clinical and Healthcare Burden of Multiple Recurrences ofClostridium difficileInfection
- (2015) Caroline Sheitoyan-Pesant et al. CLINICAL INFECTIOUS DISEASES
- Administration of Spores of NontoxigenicClostridium difficileStrain M3 for Prevention of RecurrentC difficileInfection
- (2015) Dale N. Gerding et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients
- (2015) Stefano Di Bella et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Burden of Clostridium difficile Infection in the United States
- (2015) Fernanda C. Lessa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections
- (2015) Glen P. Carter et al. mBio
- Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients
- (2014) Colleen R Kelly et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Passive and active immunization strategies against Clostridium difficile infections: State of the art
- (2014) Assaf Mizrahi et al. ANAEROBE
- Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile
- (2014) F. Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted byIn VitroNeutralization and Epitope Modeling
- (2014) Lorraine D. Hernandez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- NAP1 Strain Type Predicts Outcomes From Clostridium difficile Infection
- (2014) I. See et al. CLINICAL INFECTIOUS DISEASES
- Emergence of a Ribotype 244 Strain of Clostridium difficile Associated With Severe Disease and Related to the Epidemic Ribotype 027 Strain
- (2014) S. K. Lim et al. CLINICAL INFECTIOUS DISEASES
- Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
- (2014) Stuart Johnson et al. CLINICAL INFECTIOUS DISEASES
- The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move
- (2014) E. Valiente et al. CLINICAL MICROBIOLOGY AND INFECTION
- Review of the Emerging Treatment of Clostridium difficile Infection with Fecal Microbiota Transplantation and Insights into Future Challenges
- (2014) Zain Kassam et al. CLINICS IN LABORATORY MEDICINE
- Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab
- (2014) Zhiyong Yang et al. INFECTION AND IMMUNITY
- Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection
- (2014) Susana Fuentes et al. ISME Journal
- Antibodies to watch in 2015
- (2014) Janice M Reichert mAbs
- Multistate Point-Prevalence Survey of Health Care–Associated Infections
- (2014) Shelley S. Magill et al. NEW ENGLAND JOURNAL OF MEDICINE
- RecurrentClostridium difficileinfections: The importance of the intestinal microbiota
- (2014) Marie Céline Zanella Terrier WORLD JOURNAL OF GASTROENTEROLOGY
- Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection Among Inpatients
- (2013) Daniel E Freedberg et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Guidelines for Diagnosis, Treatment and Prevention of Clostridium difficile Infections
- (2013) Christina M Surawicz et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Relationship Between Bacterial Strain Type, Host Biomarkers, and Mortality in Clostridium difficile Infection
- (2013) A. Sarah Walker et al. CLINICAL INFECTIOUS DISEASES
- European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection
- (2013) S.B. Debast et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis
- (2013) Claudia Slimings et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Importance of Toxin A, Toxin B, and CDT in Virulence of an Epidemic Clostridium difficile Strain
- (2013) Sarah A. Kuehne et al. JOURNAL OF INFECTIOUS DISEASES
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
- (2013) Els van Nood et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection, Treatment, and Prevention of Clostridium difficile Infection
- (2012) David L. McCollum et al. Clinical Gastroenterology and Hepatology
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Antibody Against TcdB, but Not TcdA, Prevents Development of Gastrointestinal and Systemic Clostridium difficile Disease
- (2012) Jennifer Steele et al. JOURNAL OF INFECTIOUS DISEASES
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
- (2011) A. A. Venugopal et al. CLINICAL INFECTIOUS DISEASES
- The host immune response to Clostridium difficile
- (2011) C. P. Kelly et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of toxin A and toxin B in Clostridium difficile infection
- (2010) Sarah A. Kuehne et al. NATURE
- Treatment with Monoclonal Antibodies againstClostridium difficileToxins
- (2010) Israel Lowy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives
- (2010) Greg Hussack et al. Toxins
- Toxin B is essential for virulence of Clostridium difficile
- (2009) Dena Lyras et al. NATURE
- Clostridium difficile infection: new developments in epidemiology and pathogenesis
- (2009) Maja Rupnik et al. NATURE REVIEWS MICROBIOLOGY
- Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
- (2009) Brett A. Leav et al. VACCINE
- Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium
- (2009) Richard A Stabler et al. GENOME BIOLOGY
- Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection
- (2008) Mary Y. Hu et al. GASTROENTEROLOGY
- Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
- (2008) K.W. Garey et al. JOURNAL OF HOSPITAL INFECTION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now